{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:33:25Z","timestamp":1790984005885,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.hoc.2004.09.003","type":"journal-article","created":{"date-parts":[[2005,4,23]],"date-time":"2005-04-23T07:59:38Z","timestamp":1114243178000},"page":"1-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Unfractionated Heparin, Low Molecular Weight Heparins, and Pentasaccharide: Basic Mechanism of Actions, Pharmacology, and Clinical Use"],"prefix":"10.1016","volume":"19","author":[{"given":"Rodger L.","family":"Bick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene P.","family":"Frenkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Walenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawed","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Hoppensteadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2004.09.003_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/108925320300700402","article-title":"Unfractionated and low-molecular-weight heparins basic mechanisms of action ad pharmacology","volume":"7","author":"Fareed","year":"2003","journal-title":"Semin Cardiothorac Vascu Anesth"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib2","first-page":"5","article-title":"Production and chemical processing of low molecular weight heparins","volume":"25","author":"Linhardt","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib3","first-page":"17","article-title":"Structural characterization of low nolecular weight heparins","volume":"25","author":"Casu","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.hoc.2004.09.003_bib4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0038-1642434","article-title":"Ex vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin","volume":"71","author":"Young","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00001721-199601000-00003","article-title":"Inhibition of thrombin generation by heparin and LMW heparins: a comparison of chromogenic and clotting methods","volume":"7","author":"Houbouyan","year":"1996","journal-title":"Blood Coag Fibrinolysis"},{"issue":"1","key":"10.1016\/j.hoc.2004.09.003_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0735-1097(00)00695-1","article-title":"Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina","volume":"36","author":"Montalescot","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hoc.2004.09.003_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0735-1097(02)02762-6","article-title":"The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration","volume":"41","author":"Marmur","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib8","first-page":"35","article-title":"Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo\u2014studies of venous and arterial thrombosis","volume":"25","author":"Kaiser","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib9","first-page":"43","article-title":"Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine","volume":"25","author":"Dietrich","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib10","first-page":"57","article-title":"Human pharmacokinetics of low molecular weight heparins","volume":"25","author":"Cornelli","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib11","first-page":"63","article-title":"Preclinical differentiation of low molecular weight heparins","volume":"25","author":"Nader","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib12","first-page":"51","article-title":"Pharmacokinetics of low molecular weight heparins in animal models","volume":"25","author":"Fareed","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib13","first-page":"135","article-title":"Clinical differentiation of low molecular weight heparins","volume":"25","author":"Mammen","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"14","key":"10.1016\/j.hoc.2004.09.003_bib14","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1993.03510140024010","article-title":"From the Food and Drug Administration","volume":"270","author":"Nightingale","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2004.09.003_bib15","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1345\/aph.10264","article-title":"Therapeutic equivalency of low molecular weight heparins","volume":"36","author":"McCart","year":"2002","journal-title":"Ann Pharmcother"},{"key":"10.1016\/j.hoc.2004.09.003_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1538-7836.2003.00017.x","article-title":"Low molecular weight heparins: are they interchangeable? No","volume":"1","author":"Nenci","year":"2003","journal-title":"J Thromb Hemostasis"},{"issue":"3","key":"10.1016\/j.hoc.2004.09.003_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1011969005756","article-title":"Applying scientific criteria to therapeutic interchange: a balanced analysis of low molecular weight heparins","volume":"11","author":"Merli","year":"2001","journal-title":"J Thromb Thrombolysis"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib18","first-page":"113","article-title":"Low molecular weight heparins in the management of unstable angina\/non-Q-wave myocardial infarction","volume":"25","author":"Cohen","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib19","first-page":"123","article-title":"Differentiation of low molecular weight heparins in acute coronary syndromes: an interventionalist's perspective","volume":"25","author":"Gulba","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib20","unstructured":"Leong W., Hoppensteadt D.A. Generic forms of low molecular weight heparins. Some practical issues. Clin Appl Thromb Hemost, in press"},{"issue":"3","key":"10.1016\/j.hoc.2004.09.003_bib21","volume":"25","year":"1999","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2004.09.003_bib22","first-page":"3","article-title":"Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins","volume":"18","author":"Fareed","year":"1988","journal-title":"Haemostasis"},{"issue":"1","key":"10.1016\/j.hoc.2004.09.003_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-2007-1004360","article-title":"Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments","volume":"11","author":"Fareed","year":"1985","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib24","series-title":"Bush acts to speed generics to market","first-page":"A3","volume":"vol. CCXLI 114","author":"Abboud","year":"2003"},{"issue":"Suppl 556","key":"10.1016\/j.hoc.2004.09.003_bib25","first-page":"68","article-title":"Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin","volume":"156","author":"Dawes","year":"1990","journal-title":"Acta Chirur Scand"},{"key":"10.1016\/j.hoc.2004.09.003_bib26","first-page":"123","article-title":"Laboratory studies on the intravenous and subcutaneous adminstration of PK 10169 in man","volume":"16","author":"Fareed","year":"1986","journal-title":"Haemostasis"},{"key":"10.1016\/j.hoc.2004.09.003_bib27","first-page":"577","article-title":"Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers","volume":"40","author":"Azizi","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hoc.2004.09.003_bib28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1055\/s-0038-1653833","article-title":"Comparison of pharmacokinetic profiles of three low molecular mass heparins: dalteparin, enoxaparin and nadroparin: adminstered subcutaneously in healthy volunteers (doses for prevention in thromboembolism)","volume":"73","author":"Collignon","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-0038-1653787","article-title":"A comparative study of threee low molecular weight heparins (LMWH) and Unfractionated heparin (UH) in healthy volunteers","volume":"73","author":"Eriksson","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/j.1552-4604.1988.tb03184.x","article-title":"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg","volume":"28","author":"Frydman","year":"1988","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2004.09.003_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2000-9497","article-title":"Comparative pharmacokinetics of LMWHs","volume":"26","author":"Samama","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0038-1642435","article-title":"Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin: a three way cross-over study in human volunteers","volume":"71","author":"Bendetowicz","year":"1994","journal-title":"Thromb Haemost"},{"issue":"Suppl 5","key":"10.1016\/j.hoc.2004.09.003_bib33","doi-asserted-by":"crossref","first-page":"489S","DOI":"10.1378\/chest.114.5_Supplement.489S","article-title":"Heparin and low molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring efficacy and safety","volume":"114","author":"Hirsh","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.hoc.2004.09.003_bib34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0049-3848(93)90233-E","article-title":"Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation and release of tissue factor pathway inhibitor","volume":"69","author":"Bara","year":"1993","journal-title":"Thromb Res"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2004.09.003_bib35","first-page":"24","article-title":"Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans","volume":"26","author":"Frydman","year":"1996","journal-title":"Hemostasis"},{"key":"10.1016\/j.hoc.2004.09.003_bib36","first-page":"65","article-title":"Pharmacokinetics of low molecular weight heparins","volume":"543","author":"Bara","year":"1988","journal-title":"Acta Chir Scand Suppl"},{"issue":"12","key":"10.1016\/j.hoc.2004.09.003_bib37","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","article-title":"Pharmacodynamic and pharmacokinetic properties of enoxaparin. Implications for clincial practice","volume":"42","author":"Fareed","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.hoc.2004.09.003_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2004.09.003_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC)","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2004.09.003_bib40","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","volume":"20","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hoc.2004.09.003_bib41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib42","first-page":"519","volume":"90","author":"Klein","year":"2003","journal-title":"Patterns of use of heparins in ACS correlates and hospital outcomes: the Global Registry of Acute Coronary Events"},{"issue":"2","key":"10.1016\/j.hoc.2004.09.003_bib43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.160.2.229","article-title":"Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group","volume":"160","author":"Hull","year":"2000","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.hoc.2004.09.003_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(97)00042-X","article-title":"State-of-the-art article. Biochemiccal and pharmacologic rationale for the development of a heparin pentasaccharide","volume":"86","author":"Walenga","year":"1997","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.hoc.2004.09.003_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543784.11.3.397","article-title":"Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent","volume":"11","author":"Walenga","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hoc.2004.09.003_bib46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement","volume":"344","author":"Turpie","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib47","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2004.09.003_bib48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0049-3848(97)00227-2","article-title":"Efficacy of pentasaccharide in a dog model of hemodialysis","volume":"88","author":"Hoppensteadt","year":"1997","journal-title":"Thromb Res"},{"key":"10.1016\/j.hoc.2004.09.003_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0889-8588(02)00091-6","article-title":"Heparin, low molecular weight heparins and heparin pentasaccharide: basic and clinical differentiation","volume":"17","author":"Hoppensteadt","year":"2003","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.hoc.2004.09.003_bib50","first-page":"1410","article-title":"The effect of commercial heparin on the platelet count","volume":"33","author":"Fedlar","year":"1948","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archinte.1978.03630280030014","article-title":"Heparin-induced thrombocytopenia","volume":"138","author":"Nelson","year":"1978","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-0038-1650013","article-title":"Heparin induced thrombocytopenia: a prospective study","volume":"43","author":"Ansell","year":"1980","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib53","doi-asserted-by":"crossref","first-page":"535","DOI":"10.7326\/0003-4819-100-4-535","article-title":"Heparin associated thrombocytopenia","volume":"100","author":"King","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib54","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0609.1989.tb00290.x","article-title":"The mechanism of heparin-induced platelet aggregation","volume":"43","author":"Chong","year":"1989","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2004.09.003_bib55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0889-8588(18)30515-X","article-title":"Heparin and platelets","volume":"4","author":"Warkentin","year":"1990","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.hoc.2004.09.003_bib56","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2141.1993.tb03072.x","article-title":"Heparin induced thrombocytopenia and thrombosis: clinical and laboratory studies","volume":"84","author":"Boshkov","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2004.09.003_bib57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.1995.tb08346.x","article-title":"Heparin induced thrombocytopenia","volume":"89","author":"Chong","year":"1995","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.hoc.2004.09.003_bib58","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM199505183322011","article-title":"Heparin-induced thrombocytopenia and thrombosis","volume":"332","author":"Aster","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib59","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ajcp\/104.6.611","article-title":"Diagnosis of heparin-induced thrombocytopenia: still a journey, not yet a destination [editorial]","volume":"104","author":"Kelton","year":"1995","journal-title":"Am J Clin Path"},{"key":"10.1016\/j.hoc.2004.09.003_bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00000441-199304000-00003","article-title":"Heparin associated thrombocytopenia: a critical review and pooled analysis","volume":"305","author":"Schmitt","year":"1993","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.hoc.2004.09.003_bib61","first-page":"1764","article-title":"Heparin induced thrombocytopenia thrombosis after cardiopulmonary bypass","volume":"14","author":"Mumer","year":"1994","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.hoc.2004.09.003_bib62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1053-0770(05)80018-7","article-title":"Heparin induced thrombocytopenia","volume":"10","author":"Shorten","year":"1996","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.hoc.2004.09.003_bib63","first-page":"284","article-title":"Heparin induced thrombocytopenia: pathophysiology","volume":"9","author":"Kibbe","year":"1996","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.hoc.2004.09.003_bib64","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A 14 year study of heparin induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0039-6060(97)90312-3","article-title":"Diagnosis of heparin induced thromboctypenia in the vascular surgery patient","volume":"121","author":"Jackson","year":"1997","journal-title":"Surgery"},{"key":"10.1016\/j.hoc.2004.09.003_bib66","first-page":"123","article-title":"Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy","volume":"2","author":"Walenga","year":"1998","journal-title":"Cardiol Clin Ann Drug Ther"},{"key":"10.1016\/j.hoc.2004.09.003_bib67","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0025-7125(05)70015-8","article-title":"Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy","volume":"82","author":"Walenga","year":"1998","journal-title":"Med Clin N Am"},{"key":"10.1016\/j.hoc.2004.09.003_bib68","doi-asserted-by":"crossref","first-page":"259S","DOI":"10.1378\/chest.108.4_Supplement.258S","article-title":"Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"108","author":"Hirsh","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.hoc.2004.09.003_bib69","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0888-6296(90)90242-8","article-title":"Heparin-induced thrombocytopenia: a possible complication of heparin-coated pulmonary artery catheters","volume":"4","author":"Moberg","year":"1990","journal-title":"J Cardiothorac Anesth"},{"key":"10.1016\/j.hoc.2004.09.003_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archsurg.1958.01280200041005","article-title":"Arterial embolism occurring during systemic heparin therapy","volume":"76","author":"Weismann","year":"1958","journal-title":"Arch Surg"},{"key":"10.1016\/j.hoc.2004.09.003_bib71","first-page":"846","article-title":"Heparin-induced thrombocytopenia is a cause of thromboembolism following coronary by-pass surgery [abstract]","volume":"86","author":"Abhyankar","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2004.09.003_bib72","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/archsurg.1979.01370280026004","article-title":"White clot syndrome: peripheral vascular complications of heparin therapy","volume":"114","author":"Towne","year":"1979","journal-title":"Arch Surg"},{"key":"10.1016\/j.hoc.2004.09.003_bib73","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007611-198805000-00018","article-title":"White clot syndrome","volume":"81","author":"Stanton","year":"1988","journal-title":"South Med J"},{"key":"10.1016\/j.hoc.2004.09.003_bib74","first-page":"618","article-title":"Venous gangrene associated with heparin-induced thrombocytopenia","volume":"97","author":"Battey","year":"1985","journal-title":"Surgery"},{"key":"10.1016\/j.hoc.2004.09.003_bib75","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/0003-4975(90)90008-T","article-title":"Intraoperative management of patients with heparin-induced thrombocytopenia","volume":"49","author":"Kappa","year":"1990","journal-title":"Ann Throac Surg"},{"key":"10.1016\/j.hoc.2004.09.003_bib76","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00000441-198409000-00003","article-title":"Thrombocytopenia in a prospective, randomized, double blind trial of bovine and porcine heparin","volume":"288","author":"Green","year":"1984","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.hoc.2004.09.003_bib77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0049-3848(84)90083-5","article-title":"Studies on the frequency of heparin-associated thrombocytopenia","volume":"33","author":"Powers","year":"1984","journal-title":"Thromb Res"},{"key":"10.1016\/j.hoc.2004.09.003_bib78","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1378\/chest.88.6.878","article-title":"Heparin induced thrombocytopenia: what is its real frequency?","volume":"88","author":"Ansell","year":"1985","journal-title":"Chest"},{"key":"10.1016\/j.hoc.2004.09.003_bib79","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib80","first-page":"1","article-title":"Heparin prophylaxis and treatment of venous thromboembolism","volume":"15","author":"Thomas","year":"1978","journal-title":"Semin Hematol"},{"issue":"Suppl","key":"10.1016\/j.hoc.2004.09.003_bib81","first-page":"489","article-title":"heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety","volume":"114","author":"Hirsh","year":"1988","journal-title":"Chest"},{"issue":"Suppl","key":"10.1016\/j.hoc.2004.09.003_bib82","first-page":"9","article-title":"Clinical presentation of heparin-induced thrombocytopenia","volume":"35","author":"Warkentin","year":"1998","journal-title":"Semin Hematol"},{"issue":"Suppl","key":"10.1016\/j.hoc.2004.09.003_bib83","first-page":"17","article-title":"Limitations of conventional treatment options for heparin-induced thrombocytopenia","volume":"35","author":"Warkentin","year":"1998","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2004.09.003_bib84","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1583\/1074-6218(1998)005<0282:HATMOA>2.0.CO;2","article-title":"Hypercoagulability and the management of anticoagulant therapy in surgical patients: review and recommendations","volume":"5","author":"Neverre","year":"1998","journal-title":"J Endovasc Surg"},{"key":"10.1016\/j.hoc.2004.09.003_bib85","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(96)91200-3","article-title":"Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin CGP 39393","volume":"347","author":"Eriksson","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2004.09.003_bib86","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.1980.03310110019020","article-title":"Prediction of bleeding during heparin therapy","volume":"244","author":"Walker","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2004.09.003_bib87","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJM197505152922002","article-title":"Management of heparin therapy","volume":"292","author":"Salzman","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-2007-1003533","article-title":"Hemorrhagic complications of anticoagulant therapy","volume":"12","author":"Levine","year":"1986","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib89","first-page":"1565","article-title":"Heparin","volume":"327","author":"Hirsh","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib90","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(86)91421-2","article-title":"Heparin doses and major bleedings","volume":"1","author":"Morabia","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2004.09.003_bib91","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJM197805112981919","article-title":"The hazards of aspirin plus heparin","volume":"298","author":"Yett","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib93","first-page":"160","article-title":"Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin induced thrombocytopenia [abstract]","volume":"80","author":"Warkentin","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2004.09.003_bib94","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jama.1965.03090020072024","article-title":"Multiple fractures associated with long-term sodium heparin therapy","volume":"193","author":"Jaffe","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2004.09.003_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2007-1003535","article-title":"Non-hemorrhagic complications of anticoagulant therapy","volume":"12","author":"Levine","year":"1986","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib96","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1471-0528.1983.tb06458.x","article-title":"The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial","volume":"90","author":"Howell","year":"1983","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.hoc.2004.09.003_bib97","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0038-1642376","article-title":"Comparison of subcutaneous unfractionated heparin with low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin","volume":"71","author":"Monreal","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib98","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0002-9378(94)70299-3","article-title":"A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry","volume":"170","author":"Barbour","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.hoc.2004.09.003_bib99","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/0002-9378(93)90378-V","article-title":"Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin","volume":"168","author":"Dahlman","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.hoc.2004.09.003_bib100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0038-1655903","article-title":"Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies","volume":"77","author":"Hunt","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib101","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0038-1650255","article-title":"The effects of long-term therapy during pregnancy on bone density. A prospective matched cohort study","volume":"75","author":"Douketis","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib102","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V88.4.1314.bloodjournal8841314","article-title":"Histomorphometric analysis of the effects of standard heparin on trebular bone in vivo","volume":"88","author":"Muir","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2004.09.003_bib103","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood.V89.9.3236","article-title":"A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats","volume":"89","author":"Muir","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2004.09.003_bib104","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0300-9084(95)80001-8","article-title":"Heparin fails to potentiate the effects of IL-1 beta-mediated bone resorption of fetal rat long bones in vitro","volume":"77","author":"Panagakos","year":"1995","journal-title":"Biochimie"},{"key":"10.1016\/j.hoc.2004.09.003_bib105","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.V86.4.1368.bloodjournal8641368","article-title":"The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvoria","volume":"86","author":"Shaughnesy","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2004.09.003_bib106","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00001721-199504000-00004","article-title":"Long term administration of heparin and heparin fractions and osteoporosis in experimental animals","volume":"6","author":"Murray","year":"1995","journal-title":"Blood Coag Fibrinolys"},{"issue":"Suppl","key":"10.1016\/j.hoc.2004.09.003_bib107","first-page":"12","article-title":"Heparin therapy and monitoring: guidelines and practice parameters for clinical and laboratory approaches","volume":"2","author":"Bick","year":"1996","journal-title":"J Clin Appl Thromb Hemost"},{"key":"10.1016\/j.hoc.2004.09.003_bib108","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1365-2141.1996.d01-1481.x","article-title":"Heparin-induced skin lesions","volume":"92","author":"Warkentin","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2004.09.003_bib109","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00003086-197607000-00022","article-title":"An unusual complication of minidose heparin therapy","volume":"118","author":"Hill","year":"1976","journal-title":"Clin Orthop"},{"key":"10.1016\/j.hoc.2004.09.003_bib110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/00000658-197911000-00007","article-title":"Thrombotic complications of heparin therapy","volume":"190","author":"White","year":"1979","journal-title":"Ann Surg"},{"key":"10.1016\/j.hoc.2004.09.003_bib111","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.1981.03320140070035","article-title":"Cutaneous necrosis caused by systemically administered heparin","volume":"246","author":"Kelly","year":"1981","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2004.09.003_bib112","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.1980.03310160047027","article-title":"Heparin necrosis an anticoagulation syndrome","volume":"244","author":"Hall","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2004.09.003_bib113","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archderm.1983.01650290040014","article-title":"Heparin-induced cutaneous necrosis unrelated to injection sites","volume":"119","author":"Levine","year":"1983","journal-title":"Arch Derm"},{"key":"10.1016\/j.hoc.2004.09.003_bib114","first-page":"861","article-title":"Skin lesions, hypereoinophilia and subcutaneous heparin","volume":"343","author":"Bircher","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib115","first-page":"1371","article-title":"Hypereosinophilia and subcutaneous heparin","volume":"342","author":"Giustolisi","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2004.09.003_bib116","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.1981.03320190047027","article-title":"Heparin-induced hypoaldosteronism","volume":"246","author":"Lechy","year":"1981","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2004.09.003_bib117","first-page":"244","article-title":"Heparin-induced hyperkalemia","volume":"24","author":"Aull","year":"1990","journal-title":"Ann Pharmacother"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858804001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858804001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:37:50Z","timestamp":1760182670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858804001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0889858804001121"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2004.09.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unfractionated Heparin, Low Molecular Weight Heparins, and Pentasaccharide: Basic Mechanism of Actions, Pharmacology, and Clinical Use","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2004.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}